Impact on survival of tobacco smoking for cases with oropharyngeal squamous cell carcinoma and known human papillomavirus and p16-status: a multicenter retrospective study.
human papillomavirus
oropharyngeal cancer
smoking
survival
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
01
05
2019
accepted:
29
06
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
7
8
2019
Statut:
epublish
Résumé
Human papilloma virus (HPV) and tobacco smoking are important risk factors for development of oropharyngeal squamous cell carcinoma (OPSCC). To evaluate the impact of tobacco smoking on survival for cases with OPSCC with known HPV- and p16INK4A(p16)-status. OPSCC cases at the University Hospital of Copenhagen, Rigshospitalet, Denmark (2000-2014) and at University Hospital of Giessen, Germany (2000-2009) were included. Survival was illustrated with Kaplan-Meier plots. The effect of smoking exposure on survival was evaluated by Cox-regression models. HPV-positivity was defined as positivity for both HPV-DNA and p16. We included 1316 OPSCC cases from 2000-2014 (48% HPV-positive). Smokers had a poorer outcome compared to non-smokers. Considering continuous smoking exposure, adding 10 pack-years of smoking increased hazard ratios irrespective of HPV-status.We observed a tendency to a greater impact on survival for cases with HPV-neg. tumours compared to cases with HPV-pos. tumours at low numbers of pack-years, yet the survival was similar at high numbers of pack-years. There was no significant difference in the impact of HPV-status on survival for non-smokers, however a highly significant difference for smokers. Smoking-status and number of pack-years at time of diagnosis impact survival for cases with OPSCC independent of HPV-status.
Sections du résumé
BACKGROUND
BACKGROUND
Human papilloma virus (HPV) and tobacco smoking are important risk factors for development of oropharyngeal squamous cell carcinoma (OPSCC).
AIMS/OBJECTIVES
OBJECTIVE
To evaluate the impact of tobacco smoking on survival for cases with OPSCC with known HPV- and p16INK4A(p16)-status.
MATERIALS AND METHODS
METHODS
OPSCC cases at the University Hospital of Copenhagen, Rigshospitalet, Denmark (2000-2014) and at University Hospital of Giessen, Germany (2000-2009) were included. Survival was illustrated with Kaplan-Meier plots. The effect of smoking exposure on survival was evaluated by Cox-regression models. HPV-positivity was defined as positivity for both HPV-DNA and p16.
RESULTS
RESULTS
We included 1316 OPSCC cases from 2000-2014 (48% HPV-positive). Smokers had a poorer outcome compared to non-smokers. Considering continuous smoking exposure, adding 10 pack-years of smoking increased hazard ratios irrespective of HPV-status.We observed a tendency to a greater impact on survival for cases with HPV-neg. tumours compared to cases with HPV-pos. tumours at low numbers of pack-years, yet the survival was similar at high numbers of pack-years. There was no significant difference in the impact of HPV-status on survival for non-smokers, however a highly significant difference for smokers.
CONCLUSIONS AND SIGNIFICANCE
CONCLUSIONS
Smoking-status and number of pack-years at time of diagnosis impact survival for cases with OPSCC independent of HPV-status.
Identifiants
pubmed: 31384393
doi: 10.18632/oncotarget.27079
pii: 27079
pmc: PMC6659794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4655-4663Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Références
Int J Cancer. 2008 Apr 1;122(7):1679-83
pubmed: 18059031
Int J Cancer. 2008 Jun 15;122(12):2656-64
pubmed: 18360824
Int J Cancer. 2009 Jul 15;125(2):362-6
pubmed: 19330833
Acta Otolaryngol. 2011 Sep;131(9):1008-11
pubmed: 21542673
J Clin Oncol. 2012 Jun 10;30(17):2102-11
pubmed: 22565003
Br J Cancer. 2014 Mar 18;110(6):1587-94
pubmed: 24518594
Acta Otolaryngol. 2014 Sep;134(9):964-73
pubmed: 24963968
Int J Cancer. 2015 May 1;136(9):2196-203
pubmed: 25283302
Head Neck. 2016 Mar;38(3):380-6
pubmed: 25351893
Head Neck. 2016 Dec;38(12):1780-1787
pubmed: 27248701
Oncotarget. 2016 Nov 1;7(44):71761-71772
pubmed: 27708214
Eur J Cancer. 2017 Jan;70:75-82
pubmed: 27888679
Br J Cancer. 2017 Jun 6;116(12):1604-1611
pubmed: 28472822
Front Oncol. 2017 Jun 30;7:129
pubmed: 28713770
Cancer Med. 2018 Jan;7(1):87-94
pubmed: 29171183
Ann Oncol. 2018 May 1;29(5):1273-1279
pubmed: 29438466
Clin Oncol (R Coll Radiol). 2018 Jun;30(6):375-381
pubmed: 29526405
Br J Cancer. 2018 Jun;118(12):1672-1681
pubmed: 29795309
N Engl J Med. 1993 Jan 21;328(3):159-63
pubmed: 8417381